We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mr
Adam
Khan
+44 (0)121 415 9131
a.r.khan@bham.ac.uk
Prof
Mehul
Dattani
+44 (0)20 7905 2657
m.dattani@ucl.ac.uk
Dr
Study
Team
-
GHDReversal@trials.bham.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Isolated growth hormone deficiency in pubertal children
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Growth hormone (GH) is a hormone essential for normal growth and development. If a child doesn’t have enough GH, the speed of growth is slower and final adult height reduced. Growth hormone deficiency (GHD) is a condition where the pituitary gland doesn’t make enough growth hormone in childhood. GH treatment allows children with GHD to grow normally. GH is given as daily injections continued until the child reaches adult height. GH is usually given for 5-10 years and can cost £10,000-23,000 per patient per year.
Children are tested for GHD by measuring the highest amount of GH in the blood following a test. When GH production is checked after children reach their final height, some children are found to have normal levels of GH; these children therefore no longer have GHD. Some doctors think that this change occurs during puberty. Many pubertal children on GH therapy are assumed to no longer have GHD but doctors usually continue daily GH injections until the child reaches final adult height. Therefore some children continue to have potentially unnecessary, costly daily injections.
The aim of this ‘GHD Reversal’ study is to find out whether certain children can stop their GH injections at puberty and still reach a similar final adult height to those children who continue to have daily GH injections.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Multiple pituitary hormone deficiency (hypopituitarism) with or without additional pituitary hormone supplementation2. Known genetic cause of I-GHD3. Organic GHD (mid-brain tumours, congenital mid-brain malformations, septo-optic dysplasia; radiotherapy to the total body or brain)4. Ectopic posterior pituitary5. Other indications for GH therapy6. Receiving GH treatment during the (minimum 6 week) discontinuation period7. Receiving prednisolone or dexamethasone for a period of 4 weeks or longer in the time period immediately prior to randomisation8. Known history of persistent non-compliance with prescribed medication regimens9. Pregnant or lactating10. Any malignancy11. Currently participating in another Clinical Trial of an Investigational Medicinal Product (CTIMP)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.
Mr
Adam
Khan
+44 (0)121 415 9131
a.r.khan@bham.ac.uk
Dr
Study
Team
-
GHDReversal@trials.bham.ac.uk
Prof
Mehul
Dattani
+44 (0)20 7905 2657
m.dattani@ucl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University College London and funded by Health Technology Assessment Programme.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 51704
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
